Several companies claim to be engaged in the development / By Roots

In addition to enabling patients to self-medicate, these devices are designed to ensure safety during the dosing process and promote compliance to prescribed therapeutic regimens. Moreover, the adoption of autoinjectors, and other self-injection products, has enabled significant cost savings for end users by eliminating the need to visit hospitals / out-patient clinics for dosing.

To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html

The USD 2.5 billion (by 2030) financial opportunity within the global autoinjectors market has been analyzed across the following segments:

Usability

Disposable

Reusable

Route of administration

Subcutaneous

Intramuscular

Type of molecule

Antibody

Peptide

Protein

Small molecule

Therapeutic indication

Anaphylaxis

Diabetes

Migraine

Multiple sclerosis

Rheumatoid arthritis

Other indications

Key geographical regions

North America

Europe

Asia-Pacific

Rest of the World

The Global Autoinjectors Market (3rd Edition), 2020-2030. report features the following companies, which we identified to be key players in this domain:

Antares Pharma

Consort Medical (Previously Bespak)

DALI Medical Devices

Elcam Medical (E3D Elcam Drug Delivery Devices)

Jiangsu Delfu Medical Devices

Oval Medical Technologies

Owen Mumford

SHL Group

Union Medico®

Ypsomed

Table of Contents

1. Preface